Clinical trials: Amyloid Beta-protein
Alzheimer Disease
Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I AV94, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in…
- Trial name
- AV94 (NCT00605059)
- Testing
- [123I]AV94
- Where
- 2 sites in United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Alzheimer Disease
Evaluation of [123I] AV151 and SPECT in Subjects w/ AD in Comparison to Healthy Subjects
Purpose: The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I AV151, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography…
- Trial name
- AV151 (NCT00605046)
- Testing
- SPECT scan
- Where
- 2 sites in United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Bioavailability, Gut Microbiome
Curcumin and Retinal Study
To test how two weeks of curcumin supplementation would cross the blood brain barrier (BBB) and attach to amyloid beta proteins, to assess the feasibility (safety and bioavailability), and to explore the resulting…
- Conditions
- Bioavailability, Gut Microbiome, Safety
- Trial name
- NCT05774704
- Testing
- Low curcumin group, High curcumin group
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Texas Tech University Health Sciences Center
Obstructive Sleep Apnea, Alzheimer's Disease
Brain Sleep Clearance of Amyloid-Beta Peptides
The 'Amyloid Cascade Hypothesis' posits that the accumulation of a peptide, amyloid beta (Aβ), in the brain is the initiating event in Alzheimer's disease (AD), however, the mechanisms involved are not well understood.
- Trial name
- Brain SCRAPs (NCT02474251)
- Testing
- Continuous positive airway pressure device
- Where
- 2 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Alzheimers Disease
Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects
The underlying goal of this study is to assess 123-I AV39 SPECT imaging as a tool to detect ß-amyloid deposition in the brain of AD research participants and age- and gender-matched healthy subjects.
- Trial name
- NCT00439010
- Testing
- [123I] AV 39
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Molecular NeuroImaging
Amyloid Beta Protein
Escitalopram Effects on CSF Amyloid Beta
Alzheimers disease (AD) is a devastating illness, estimated to affect 5 million patients in the United States alone and projected to increase dramatically over the next decades as the population ages unless preventive measures…
- Trial name
- NCT02161458
- Testing
- Escitalopram 20mg for 2 weeks, Escitalopram 20mg for 8 weeks, Escitalopram 30mg for 8 weeks
- Where
- 2 sites in United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Alzheimers Disease
Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls
The underlying goal of this study is to assess 123-I AV83 SPECT imaging as a tool to detect ß-amyloid deposition in the brain of AD research participants and age- and gender-matched healthy subjects.
- Trial name
- NCT00448799
- Testing
- [123-I] AV-83 Injection and Imaging Procedures
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Molecular NeuroImaging
Alzheimer's Disease (AD), Neurodegenerative Disease
A Biomarker-chip Assay in Preserved Red Blood Cells for the Diagnosis of Alzheimer's Disease
The ADCHIP study (ST0067) is a non-interventional, monocentric, prospective study conducted by Amoneta Diagnostics and the Leenaards Memory Center (Lausanne, Switzerland).
- Conditions
- Alzheimer's Disease (AD), Neurodegenerative Disease, Dementia, Frontotemporal Dementia (FTD)
- Trial name
- ADCHIP (NCT07307872)
- Where
- Switzerland
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Alzheimer Disease, Amyloid Beta-Peptides
Risk Evaluation and Education for Alzheimer's Disease - the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN)
This study is intended to examine the impact of learning amyloid brain imaging results among asymptomatic older adults, and how to safely communicate these results and educate on the risk of developing Alzheimer's disease.
- Conditions
- Alzheimer Disease, Amyloid Beta-Peptides, Risk Assessment, Education
- Trial name
- REVEAL-SCAN (NCT02959489)
- Testing
- Alzheimer's Disease Risk Disclosure, Amyloid Brain Imaging and Alzheimer's Disease Risk Disclosure
- Where
- 4 sites in United States
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Alzheimer's Disease
Single Photon Emission Computed Tomography (SPECT) Imaging Study to Develop a Biomarker for Alzheimer's Disease
The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I MNI-388 and MNI 390, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed…
- Trial name
- NCT00886951
- Testing
- I123MNI388/I123MNI390
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Alzheimer Disease
Effects of Sleep Deprivation on Cerebrospinal Fluid (CSF) Amyloid-beta (Aβ) Dynamics
Introduction: Alzheimer's disease (AD) is characterized by neurodegeneration of the brain in the form of neurofibrillary tangles and plaques containing the amyloid-beta protein (Abeta).
- Trial name
- AWAKE (NCT01194713)
- Testing
- Sleep deprivation
- Where
- Netherlands
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University Medical Center Nijmegen
Down Syndrome, Amyloid Beta-protein
Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.
To determine the sensitivity of the visual assessment of BAY94-9172 PET images in detecting cerebral β-amyloid in individuals with Down Syndrome (DS) and specificity in individuals without DS.
- Trial name
- NCT00928304
- Testing
- Florbetaben (BAY94-9172)
- Where
- 2 sites in United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Lantheus Biosciences Ltd.
Alzheimer s Disease, Major Depressive Disorder (MDD)
VR Pupillometry in Cognitive Impairment
With disease-modifying therapies emerging for dementia and related conditions, identifying cognitive decline as early as possible is increasingly important.
- Conditions
- Alzheimer s Disease, Major Depressive Disorder (MDD), Mild Cognitive Impairment, Dementia
- Trial name
- NCT07402356
- Where
- Germany
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Max-Planck-Institute of Psychiatry
Alzheimer Disease, Dementia
Exploratory Clinical Study and Validation of Blood Biomarkers for Alzheimer's Disease
This is a 24-month, monocentric, exploratory and observational clinical study aimed at developing and validating a blood-based diagnostic test for Alzheimer's disease (AD).
- Conditions
- Alzheimer Disease, Dementia, Neurodegenerative Disorders, Cognitive Decline
- Trial name
- ADKIT (NCT07294586)
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Alzheimer Disease
Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in AD Subjects Compared to HC
The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I MNI-308, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT)…
- Trial name
- NCT00544453
- Testing
- [123I] MNI-308
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Molecular NeuroImaging
Alzheimer Disease
Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau
This study will look at the effects of lemborexant on Alzheimer's disease biomarkers found in the cerebrospinal fluid (CSF) and blood in individuals who are poor sleepers
- Trial name
- NCT05728736
- Testing
- Lemborexant 25 mg
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Brendan Lucey
Elderly Individuals Aged 60 Years or Older, Mild Cognitive Impairment (MCI)
THE EFFECTS OF GAMBIR CATECHIN (UNCARIA GAMBIR ROXB) SUPPLEMENTATION ON COGNITIVE FUNCTION, EXPRESSION OF APP, MAPT, BDNF, IL-10, TGF-Β GENES, AND PLASMA MDA LEVELS IN THE ELDERLY.
Objective The primary objective of this clinical trial is to investigate the effects of gambir catechin administration on cognitive function, the expression of amyloid precursor protein (APP), microtubule-associated protein tau…
- Trial name
- NCT06604390
- Testing
- catechin extracts (health food), plasebo
- Where
- 2 sites in Fiji, Indonesia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Rahmi Novita Yusuf
Alzheimer Disease
Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition
The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I MNI-330, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT)…
- Trial name
- NCT00657813
- Testing
- MNI-330 as a brain SPECT tracer of Beta-Amyloid
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Alzheimer Disease
Amyloid Beta-peptide 1-40 and Alzheimer's Disease
The combined measurement of Ab42 and tau protein (total and phosphorylated) in the spinal fluid has been shown to be promising in the diagnosis of Alzheimer's disease (AD), and has justified its inclusion new diagnostic criteria.
- Trial name
- ADAB40 (NCT02770482)
- Testing
- spinal fluid collection
- Where
- France
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- CHU de Reims
Healthy Aging, Brain Health
Assessing the Influence of Habitual Beef Intake on Key Molecular Markers of Brain Health
his study investigates whether eating lean beef every day can help support brain health and healthy aging in older adults. As people age, protecting memory and cognitive function becomes increasingly important.
- Conditions
- Healthy Aging, Brain Health, Cardiometabolic Health, Normal Aging
- Trial name
- NCT07623785
- Testing
- Lean Beef, Non-Beef Control
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- South Dakota State University